Navigation Links
Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension

Next Generation Renin Inhibitor to Continue Phase II Profiling in Diabetic Patients


BASEL/Switzerland and BRIDGEWATER NJ/USA, 28 June 2007-Speedel (SWX: SPPN) today announced that it has reached another significant milestone in the development of its family of renin inhibitors with the successful completion of a Phase IIa proof-of-concept clinical trial with SPP635 for the treatment of hypertension. Based on these positive results, the company is to continue developing SPP635 in Phase II in a special population of diabetic patients with mild-to-moderate hypertension. This compound is the first of a next generation of renin inhibitors following Speedel's lead product SPP100 (aliskiren, Tekturna/Rasilez[1]), which is partnered with Novartis and recently obtained US marketing approval from the FDA and a positive opinion from the CHMP in Europe[2]. SPP635 is the most advanced compound in the SPP600 series and is one of several new proprietary renin inhibitors invented by Speedel Experimenta, the company's late-stage research unit.

Phase IIa results demonstrate strong efficacy and good tolerability
The trial had a double-blind, placebo-controlled, randomised, parallel design and it evaluated patients treated with a single dosage level of SPP635 once-daily for 4 weeks. It studied the safety and efficacy of SPP635 in 35 male and female patients (20 patients receiving SPP635 and 15 receiving placebo) with mild-to-moderate hypertension by measuring office and ambulatory blood pressure[3].

SPP635 was safe and well tolerated over the 4 week period. There were no serious adverse events reported nor were there any clinically significant changes in laboratory safety parameters. Sitting systolic blood pressure was significantly reduced by 17.9 mmHg from 156.6±9.1 mmHg at baseline (mean ± SD) to 138.7±13.3 mmHg in the SPP635 treated group after 4 weeks (p<0.001). The placebo group remained unchanged (156.1&plu
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
9. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
10. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
11. Bentley Reports Positive Results with Nasulin Intranasal Insulin Spray at the American Diabetes Association Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Speedel Reports Successful SPP635 Phase IIa Trial Hypertension
(Date:7/30/2015)... 30, 2015 What can be ... areas are going to grow at the fastest rates? ... revenues to 2025, assessing data, trends, opportunities and prospects ... 176 tables, charts, and graphs. Discover the most lucrative ... Our new study lets you assess forecasted sales at ...
(Date:7/30/2015)...  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) today ... at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) ... 2015 financial results and provide a corporate update. Arena ... Select Market closes that day. The conference ... callers and 914.495.8552 for international callers. Please specify to ...
(Date:7/30/2015)... HeartWare International, Inc . (NASDAQ: HTWR ), ... support technologies that are revolutionizing the treatment of ... $73.6 million for the quarter ended June 30, ... ended June 30, 2014.  Currency fluctuations impacted revenue ... points, during the three months ended June 30, ...
Breaking Medicine Technology:Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 2Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 3Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 4Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 5Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 6Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 2Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 3Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 4HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 2HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 3HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 4HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 5HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 6HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 7HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 8HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 9HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 10HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 11HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 12HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 13HeartWare International Reports $73.6 Million In Second Quarter 2015 Revenue, Driven By Strong Global Unit Growth 14
... Ore.--(BUSINESS WIRE)--May 1, 2007 - AVI BioPharma, ... of NEUGENE(R) antisense compounds,against seasonal influenza A ... professor, Department of Microbiology and Immunology,Tulane University ... poster,form at the 20th International Conference on ...
... -- CEL-SCI,CORPORATION announces that CEL-1000 alone increased ... that the combination of,CEL-1000 with MAS-1, a ... Pharma, induced highly significant increases,in specific anti-HBV ... by Dr. Daniel Zimmerman, Senior Vice President ...
Cached Medicine Technology:AVI BioPharma Reports Positive Pre-Clinical Influenza Data 2AVI BioPharma Reports Positive Pre-Clinical Influenza Data 3CEL-SCI's Cel-1000 Shown to Significantly Enhance Immune Response,Against Hepatitis B Antigen in Animals 2
(Date:7/30/2015)... ... 2015 , ... Between 2012 and 2014 HIV infection rates rose from five ... June 17th. Those untreated heroin use disorders share their needles and spread the infection. ... throughout the community. Ultimately Florida’s HIV infection rates have bolstered to 23 percent due ...
(Date:7/30/2015)... Alexandria, VA (PRWEB) , ... July 30, 2015 ... ... applauds Drug Enforcement Administration (DEA) Acting Administrator Chuck Rosenberg’s announcement of the reinstitution ... been scheduled for Saturday, September 26, 2015 from 10:00 AM to 2:00 PM ...
(Date:7/30/2015)... PA (PRWEB) , ... July 30, 2015 , ... ... inventor from Texas, has designed a personal-care device that makes it easy to apply ... Buddy” could eliminate the need for assistance when applying lotion or medication to the ...
(Date:7/30/2015)... Washington, DC (PRWEB) , ... July 30, 2015 ... ... top global managers at multinational organizations and NGO’s, according to a new survey ... today, also shows that property damage and employee medical expenses represented the largest ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... its Medicare administrative contractor (MAC) over submitted claims for bariatric surgery that, despite ... challenge to program integrity, Becky Dennis, a nurse auditor at WellSpan Health, tells ...
Breaking Medicine News(10 mins):Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 2Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 3Health News:AAPCC Supports National Prescription Drug Take-Back Day 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 3Health News:InventHelp® Client Patents “My Back Buddy” – Device Could Apply Lotion to Hard-to-Reach Areas Easily 2Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 2Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 3Health News:Hospital Details Fight for Bariatric Surgery Reimbursement in AIS Newsletter 2Health News:Hospital Details Fight for Bariatric Surgery Reimbursement in AIS Newsletter 3
... rose during the Great Depression, study shows , ... may not be all bad. In fact, U.S. researchers ... University of Michigan researchers looked at death rates during ... 20th century. From the stock market crash of 1929 ...
... women with metastatic colorectal cancer lived longer than younger ... a benefit from estrogen or other hormones, according to ... Research , a journal of the American Association for ... that estrogen prevents colorectal cancer, but this is the ...
... of Texas Health Science Center at Houston and the ... launch a study of Jamaican children that they hope ... may interact to cause autism spectrum disorders. The ... the National Institute of Child Health and Human Development ...
... study finds, , TUESDAY, Sept. 29 (HealthDay News) -- Despite ... know about national recommendations for a minimum of 30 minutes ... goal, a new study has found. , The lack of ... in the United States, the researchers said. Their finding came ...
... Black Women,s Health Study (BWHS) of the Sloan Epidemiology ... received a five-year continuation of grant funding award from ... years 16-20 of the largest follow-up study of the ... associate director of the Slone Epidemiology Center and professor ...
... RIVERSIDE, Calif. A deadly disease, malaria afflicts 350-500 ... a million people. Transmitted by Anopheles mosquitoes, the ... with at least 40 percent of the world,s population ... is the development of an effective malaria vaccine. Yet, ...
Cached Medicine News:Health News:Could the Recession Be Good for Your Health? 2Health News:Could the Recession Be Good for Your Health? 3Health News:Could the Recession Be Good for Your Health? 4Health News:Women fare better than men with metastatic colorectal cancer -- are hormones helping? 2Health News:UT Houston, Jamaica researchers launch autism study 2Health News:UT Houston, Jamaica researchers launch autism study 3Health News:Exercise 30 Minutes a Day? Who Knew! 2Health News:Book by UCR biologist tells story of 100-year quest for elusive malaria vaccine 2Health News:Book by UCR biologist tells story of 100-year quest for elusive malaria vaccine 3Health News:Book by UCR biologist tells story of 100-year quest for elusive malaria vaccine 4
... The Calypte AwareTM HIV-1/2 OMT test is ... vitro immunoassay for the,detection of antibodies to ... Type 2 (HIV-2) in human oral,mucosal transudate ... a point-of-care aid in the clinical diagnosis ...
... The OcuLight OR (532 nm) ... green product,family. The OcuLight family is ... use, and portability and it makes,up ... ophthalmic lasers. ,The OcuLight OR laser ...
...
...
Medicine Products: